TWEAK is a known mediator of inflammatory bone remodelling [35], and targeted inhibition of the TWEAK/fibroblast growth factor inducible 14 (FnF14) signalling pathway has been proposed as a therapeutic strategy to reduce bone resorption in rheumatoid arthritis patients [36]. This evidence concerns the gene TNFSF12 and rheumatoid arthritis.